C
Last Price
52 Week Range
¥98.00 - ¥457.00
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | ¥7.45B |
EV | ¥4.90B |
Shares Outstanding | 68.99M |
Beta | - |
Industry | Medical - Pharmaceuticals |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E 2024E | - |
P/Revenue 2024E | - |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2024E | - |
Net Profit Margin 2024E | - |
ROE 2024E | - |
ROCE 2023 | - |
DPS 2024E | - |
Payout Ratio 2024E | - |
Div. Yield 2024E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
C
Chordia Therapeutics Inc.
190A
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Miyake, Hiroshi
Employees
23
Website
www.chordiatherapeutics.comIPO Date
2024-06-14
Headquarters
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012, Japan
The last closing price of Chordia Therapeutics (190A) is ¥108.00, reflecting a +0.00% change from the prior session. Last updated: January 1, 2026 at 1:34 AM Eastern Time
Review the recent 190A stock performance trends:Past 1 Month: Chordia Therapeutics (190A) shares have +2.86%.Past 3 Months: The stock has -20.00%.Past 6 Months: 190A shares have -49.06%. Last updated: January 1, 2026 at 12:10 AM Eastern Time
Over the last year, Chordia Therapeutics (190A) has established a 52-week price range between a high of ¥457.00 and a low of ¥98.00. This metric is essential for assessing the stock's annual volatility. Last updated: January 1, 2026 at 12:10 AM Eastern Time
The current Chordia Therapeutics (190A) market capitalization is approximately ¥7.45B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Chordia Therapeutics's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:10 AM Eastern Time
In the most recently reported fiscal year, Chordia Therapeutics (190A) generated net income of ¥223.34M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions.
Chordia Therapeutics (190A) does not currently pay a dividend. Over the last twelve months (LTM), the company paid ¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.
Based on the latest available analyst coverage, Chordia Therapeutics (190A) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 1:34 AM Eastern Time
Like other publicly traded stocks, Chordia Therapeutics (190A) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Chordia Therapeutics (190A) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 190A to your watchlist.
Chordia Therapeutics trades under the ticker symbol 190A on the TSE stock exchange. The ticker 190A is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, Chordia Therapeutics (190A) employs approximately 23 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:10 AM Eastern Time
Chordia Therapeutics (190A) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Chordia Therapeutics (190A) stock peers based on overlapping products, services, and competitive dynamics:Biocytogen Pharmaceuticals (Beijing) (2315)Abbisko Cayman (2256)Shandong Boan Biotechnology (6955)CANbridge Pharmaceuticals (1228)Lepu Biopharma (2157)Alphamab Oncology (9966)CStone Pharmaceuticals (2616)Genor Biopharma Holdings (6998)Sichuan Kelun-Biotech Biopharmaceutical (6990) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Chordia Therapeutics.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.